Evaluation of Protective Effect of Activated Charcoal and Probiotic Against Progression of Chronic Kidney Disease

Status

UNKNOWN

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05540431

Enrollment

Registered

2022-09-14

Start date

2022-09-25

Completion date

2023-12-20

Last updated

2022-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uremic Toxin

Keywords

Indoxyl sulfate

Brief summary

Investigate the nephroprotective effect of Activated Charcoal and Probiotic in limiting the progression of renal impairment in patients with chronic kidney disease and improving of renal function test and phosphate level. Condition or disease: chronic kidney disease

Detailed description

Chronic kidney disease (CKD) is characterized by a gradual decrease in the glomerular filtration rate (GFR) and proteinuria. CKD is a global health problem, and its incidence has been increasing. The estimated global prevalence of CKD is 8-14%. When kidney function deteriorates gradually, many metabolites accumulate in the body. These accumulated substances, termed as uremic toxins (UTs), can result in adverse pathophysiological outcomes. UTs can affect multiple organs and cause renal fibrosis, vascular calcification, anemia, peripheral arterial disease, adynamic bone disease, adipocyte dysfunction with insulin resistance, impaired immune system, and uremic pruritus. The pathophysiological mechanisms through which UTs cause multiple organ damage are complex and not completely understood. These mechanisms may include inflammation, reactive oxidative stress, cellular transdifferentiation, impaired mitochondria function, intestinal barrier destruction, and changes in intestinal microbiota.

Interventions

OTHERNo intervention

RCT

DRUGActivated Charcoal

RCT

DIETARY_SUPPLEMENTProbiotic

RCT

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Masking description

None (Open Label)

Intervention model description

Interventional (clinical trial)

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Yes

Inclusion criteria

* Patients with age more than 18 years old; * Patients with CKD; * Both genders will be included.

Exclusion criteria

* Patient with age less than 18 years old; * Inability or rejection to take activated charcoal or probiotic; * Clinically unstable; * Pregnant; * Unlikely to adhere to study procedure (eg. due to cognitive limitations, severe psychiatric disorder or alcoholism).

Design outcomes

Primary

Measure	Time frame	Description
Improving of blood urea	Baseline to 6 week	The concentration of blood urea(mmol/L),dL) ) in all blood samples
Indoxyl sulfate assay	Baseline to 6 week	The concentration of human indoxyl sulfates level by elisa technique in the subjects' blood samples
Improving of serum creatinine mg/dL	Baseline to 6 week	The concentration of serum creatinine(mg/dL) in all blood sample

Secondary

Measure	Time frame	Description
Nutrition status	Baseline to 6 week	The concentration of albumin(g/dL) in the subjects' blood samples

Countries

Iraq

Contacts

Primary ContactWaleed Khaild Rahman, Bachelor of pharmacy

ph.waleedkhaild99@gmail.com+9647809763160

Backup ContactIhsan Salah Rabea, Assistant Professor

Ihsans.mohammed@uokufa.edu.iq+9647812516401

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026